Saturday 17 October 2026 Export CLOV’s income statement to Excel — free account

Clover Health Investments, Corp.

Clover Health Investments, Corp.’s revenue for fiscal 2025 (year ended December 2025) was $1.9 billion, up 40.3% from fiscal 2024. In the quarter to June 2026, revenue grew 55.6%, EPS grew 350.0% and free cash flow grew 406.4%, each against the same quarter a year earlier. Revenue growth for three consecutive years.

4.48 0.20 −4.27%

Follow CLOV

Alert me

Market cap: $2.5B
P/E: 0.0×
Fwd P/E: 292×
Dividend yield: —
F-score: 3/9
Altman Z: 0.44
Beneish M: −1.72
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 8.14

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	1	1	2	—	2	—	3	5	10	2	6	3

Insider Ownership 21.70%

Capital & Financial Ratios $m

Market Cap 2,490.00

Revenue 2,476.71

Net Income (18.36)

Free Cash Flow 74.21

Net Debt (243.10)

Current Ratio 1.50

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E 292.00

P/S ratio 0.95

P/B ratio 6.24

Past 5Y EPS Growth —

This Y EPS Growth 55.05%

Next Y EPS Growth 79.15%

Next Y revenue growth 53.51%

Next 5Y EPS Growth 66.48%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 55.03%

10-year low 10-year high

P/B against its own 10 years 78.23%

10-year low 10-year high

EV/Sales against its own 10 years 58.33%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2019	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	236	222	120	243
Receivables	64	52	95	73
Inventory	—	—	—	—
Other	41	57	75	150
	428	343	308	485

	2023	2024	2025	Q'26
Payables	37	35	36	35
ST’ Debt	—	—	—	—
Other	143	160	157	257
	261	214	209	323

Compound Annual Growth %

	10y	5y	3y
Sales	—	23.39%	20.62%
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	0.00%	(4.72%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	749	743	—	—	—
’25	462	478	497	488	1,924
’24	347	356	331	337	1,371
’23	322	320	306	312	1,261
’22	874	847	857	(1,481)	1,097
’21	200	412	427	432	1,472
’20	166	172	169	166	673

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	108	25	—	—	—
’25	(16)	5	12	(68)	(67)
’24	26	45	50	(86)	35
’23	79	53	(19)	(258)	(145)
’22	(57)	(39)	102	(209)	(204)
’21	(93)	(64)	(45)	(80)	(282)
’20	(37)	13	(35)	(60)	(118)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	107	25	—	—	—
’25	(16)	5	11	(69)	(69)
’24	25	44	50	(86)	33
’23	79	53	(19)	(258)	(145)
’22	(57)	(39)	101	(213)	(208)
’21	(93)	(64)	(45)	(80)	(283)
’20	(37)	13	(35)	(60)	(119)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	0.05	0.05	—	—	—
’25	0.00	(0.02)	(0.05)	(0.10)	(0.17)
’24	(0.04)	0.01	(0.02)	(0.04)	(0.10)
’23	(0.15)	(0.06)	(0.09)	(0.15)	(0.44)
’22	(0.16)	(0.22)	(0.16)	(0.18)	(0.71)
’21	(0.13)	(0.78)	(0.08)	(0.44)	(1.42)
’20	(0.32)	0.02	0.05	(1.29)	(1.54)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	9.87	3.68	0.86	0.71	0.61	2.12	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	17.20	28.85	4.11	1.63	4.71	4.87
People
People	Employees	—	—	—	—	458	680	656	552	570	724
	Revenue/emp, $m	—	—	—	0.00	1.47	2.16	1.67	2.28	2.41	2.66
Income, $m
Income, $m	Revenue	—	—	—	462	673	1,472	1,097	1,261	1,371	1,924
	Gross margin, %	—	—	—	3.37	12.31	(5.38)	9.44	20.30	26.61	18.50
	EBT	—	—	—	(364)	(136)	(588)	(255)	(210)	(46)	(86)
	EBT margin, %	—	—	—	(78.69)	(20.27)	(39.93)	(23.22)	(16.67)	(3.37)	(4.45)
	Net income	—	0	—	(364)	(136)	(588)	(340)	(213)	(43)	(86)
	Depreciation	—	—	—	14	21	15	0	(2)	(1)	0
Per share, $
Per share, $	Revenue	—	—	—	5.26	7.59	3.56	2.30	2.61	2.80	3.76
	Earnings	—	—	—	(4.14)	(1.54)	(1.42)	(0.71)	(0.44)	(0.10)	(0.17)
	Cash flow	—	—	—	(1.82)	(1.34)	(0.68)	(0.43)	(0.30)	0.07	(0.13)
	Capex	—	—	—	0.00	(0.01)	0.00	(0.01)	0.00	0.00	0.00
	Free cash flow	—	—	—	(1.82)	(1.34)	(0.69)	(0.44)	(0.30)	0.07	(0.13)
	Book value	—	—	—	0.00	(6.91)	1.31	0.75	0.59	0.70	0.60
	Shares, m	—	—	—	88	89	413	476	482	490	512
Valuation, ×
Valuation, ×	P/E	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	—	—	—	0.00	2.21	1.04	0.41	0.37	1.13	0.63
	P/B	—	—	—	121,753.54	0.00	2.85	1.27	1.62	4.52	3.90
	EV/Sales	—	—	—	0.00	2.26	0.65	0.13	0.20	0.98	0.57
	EV/FCF	—	—	—	0.00	(12.73)	(3.40)	(0.67)	(1.71)	40.36	(16.01)
Cash, $m
Cash, $m	Operating cash flow	—	—	—	(160)	(118)	(282)	(204)	(145)	35	(67)
	Capex	—	—	—	0	(1)	(1)	(4)	(1)	(2)	(2)
	Free cash flow	—	—	—	(160)	(119)	(283)	(208)	(145)	33	(69)
Balance, $m
Balance, $m	Working capital	—	—	—	0	26	380	193	167	130	99
	Total debt	—	—	—	—	127	20	2	1	—	—
	Net debt	—	—	—	—	31	(595)	(333)	(236)	(222)	(120)
	Shareholders’ equity	—	—	—	0	(613)	539	357	286	341	309
Returns, %
Returns, %	ROA	—	—	—	(725,298.11)	(102.03)	(96.51)	(38.60)	(30.94)	(7.47)	(15.25)
	ROIC	—	—	—	0.00	0.00	0.00	(756.23)	(255.82)	(23.91)	(28.37)
	ROE	—	—	—	117.88	44.48	1,591.19	(75.78)	(66.34)	(13.71)	(26.33)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
ELV Elevance Health, Inc.	$92.9B	19.0×	20.3×	+1.40% (above 0%: growing)	−13.08% (below 0%: shrinking)	−9.01% (below 0%: shrinking)	15.77%	4.56%	Compare
CI Cigna Group	$79.0B	12.5×	11.4×	+6.68% (above 0%: growing)	+10.16% (above 0%: growing)	+66.93% (above 0%: growing)	88.24%	3.73%	Compare
HUM Humana Inc.	$51.9B	38.8×	42.9×	+26.18% (above 0%: growing)	+27.88% (above 0%: growing)	+58.51% (above 0%: growing)	13.45%	3.33%	Compare
CNC Centene Corporation	$34.8B	— (loss-making)	24.8×	+9.92% (above 0%: growing)	n/m	+116.61% (above 0%: growing)	8.59%	2.24%	Compare
MOH Molina Healthcare, Inc	$11.1B	— (loss-making)	55.0×	−4.84% (below 0%: shrinking)	−74.95% (below 0%: shrinking)	+5.81% (above 0%: growing)	13.19%	1.33%	Compare
OSCR Oscar Health, Inc.	$10.3B	18.6×	29.7×	+70.40% (above 0%: growing)	n/m	+316.29% (above 0%: growing)	22.25%	7.96%	Compare
CLOV Clover Health Investments, Corp.	$2.5B	— (loss-making)	292×	+55.60% (above 0%: growing)	n/m	+406.43% (above 0%: growing)	20.59%	3.77%
PGNY Progyny, Inc.	$2.1B	27.7×	19.9×	+5.30% (above 0%: growing)	+80.00% (above 0%: growing)	−12.01% (below 0%: shrinking)	25.48%	11.41%	Compare
ALHC Alignment Healthcare, Inc.	$1.7B	39.4×	80.3×	+31.55% (above 0%: growing)	+125.00% (above 0%: growing)	−229.51% (below 0%: shrinking)	13.55%	3.15%	Compare
Median of peers	$23.0B	23.4×	27.3×	+8.30%	+19.02%	+32.16%	14.66%	3.53%

All 12 Healthcare Plans stocks →

Clover Health Investments, Corp. (CLOV) key facts

Strength: Clover Health Investments, Corp.’s revenue for fiscal 2025 (year ended December 2025) was $1.9 billion, up 40.3% from fiscal 2024.
Clover Health Investments, Corp. (CLOV) is a Healthcare Plans company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, CLOV traded at $4.48, a market capitalization of $2.5 billion.
Return on equity was −26.3% and debt-to-equity 0.00.
Its Piotroski F-score is 3 out of 9 and its Altman Z-score is 0.44 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.